On July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and
invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company .
invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7 12 Per Share streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pre-Open Stock Movers 06/23: Snowflake Gains on Upgrade, Accenture Falls Post Earnings (more ) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Proposed ~US$161 million all-cash acquisition to accelerate invoX's strategy to build Sino Biopharm's International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe